电场治疗神经胶质瘤的研究进展

国际肿瘤学杂志››2017,Vol. 44››Issue (6): 464-.doi:10.3760/cma.j.issn.1673-422X.2017.06.016

电场治疗神经胶质瘤的研究进展

毛昀，李利亚

100029 北京中医药大学研究生院（毛昀）；中日友好医院中西医结合肿瘤科（毛昀、李利亚）

出版日期:2017-06-08发布日期:2017-06-16
通讯作者:李利亚 E-mail:li.liya2007@163.com
基金资助:

国家自然科学基金（81372412）

Research progress of electric field in the treatment of glioma

Mao Yun, Li Liya

Graduate School of Beijing University of Chinese Medicine; Department of Integrated Traditional Chinese and Western Medicine Oncology, ChinaJapan Friendship Hospital, Beijing 100029, China

Online:2017-06-08Published:2017-06-16
Contact:Li Liya E-mail:li.liya2007@163.com
Supported by:

National Natural Science Foundation of China (81372412)

摘要/Abstract

摘要：电场治疗肿瘤技术在神经胶质瘤的治疗中具有重要意义，其包括直流电场和交流电场。直流电场影响胶质瘤细胞的迁移，可作为治疗胶质瘤的新线索；交流电场能抑制胶质瘤细胞的增殖、侵袭并诱导凋亡，明显延长胶质瘤患者生存期及提高患者生命质量。

毛昀，李利亚. 电场治疗神经胶质瘤的研究进展[J]. 国际肿瘤学杂志, 2017, 44(6): 464-.

Mao Yun, Li Liya. Research progress of electric field in the treatment of glioma[J]. Journal of International Oncology, 2017, 44(6): 464-.

［1］ Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review［J］. JAMA, 2013, 310(17): 1842-1850. DOI: 10.1001/jama.2013.280319. ［2］ Liu Y, Yan W, Zhang W, et al. MiR218 reverses high invasiveness of glioblastoma cells by targeting the oncogenic transcription factor LEF1［J］. Oncol Rep, 2012, 28(3): 1013-1021. DOI: 10.3892/or.2012.1902. ［3］ Griffin M, Iqbal SA, Sebastian A, et al. Degenerate wave and capacitive coupling increase human MSC invasion and proliferation while reducing cytotoxicity in an in vitro wound healing model［J］. PLoS One, 2011, 6 (8): e23404. DOI: 10.1371/journal.pone.0023404. ［4］ Creecy CM, O′neill CF, Arulanandam BP, et al. Mesenchymal stem cell osteodifferentiation in response to alternating electric current［J］. Tissue Eng Part A, 2013, 19(34): 467-474. DOI: 10.1089/ten.tea.2012.0091. ［5］ Zhao Z, Watt C, Karystinou A, et al. Directed migration of human bone marrow mesenchymal stem cells in a physiological direct current electric field［J］. Eur Cell Mater, 2011, 22: 344-358. ［6］ Yamashita M. Fluctuations in nuclear envelope′s potential mediate synchronization of early neural activity［J］. Biochem Biophys Res Commun, 2011, 406(1): 107-111. DOI: 10.1016/j.bbrc.2011.02.004. ［7］ Cuzick J, Holland R, Barth V, et al. Electropotential measurements as a new diagnostic modality for breast cancer［J］. Lancet, 1998, 352 (9125): 359-363. ［8］ Mycielska ME, Djamgoz MB. Cellular mechanisms of directcurrent electric field effects: galvanotaxis and metastatic disease［J］. J Cell Sci, 2004, 117 (Pt 9): 1631-1639. ［9］ Cao L, Wei D, Reid B, et al. Endogenous electric currents might guide rostral migration of neuroblasts［J］. EMBO Rep, 2013, 14(2): 184-190. DOI: 10.1038/embor.2012.215. ［10］ Cuddapah VA, Robel S, Watkins S, et al. A neurocentric perspective on glioma invasion［J］. Nat Rev Neurosci, 2014, 15(7): 455-465. DOI: 10.1038/nrn3765. ［11］李飞. 脑胶质瘤侵袭生长的相关因素及直流电场诱导U87胶质瘤细胞定向迁移［D］. 重庆: 第三军医大学, 2011. ［12］ Li F, Chen T, Hu S, et al. Superoxide mediates direct current electric fieldinduced directional migration of glioma cells through the activation of AKT and ERK［J］. PLoS One, 2013, 8(4): e61195. DOI: 10.1371/journal.pone.0061195. ［13］ Huang YJ, Hoffmann G, Wheeler B, et al. Cellular microenvironment modulates the galvanotaxis of brain tumor initiating cells［J］. Sci Rep, 2016, 6: 21583. DOI: 10.1038/srep21583. ［14］ Wu S, Wang Y, Guo J, et al. Nanosecond pulsed electric fields as a novel drug free therapy for breast cancer: an in vivo study［J］. Cancer Lett, 2014, 343(2): 268-274. DOI: 10.1016/j.canlet.2013.09.032. ［15］ Guo F, Yao C, Li C, et al. In vivo evidences of nanosecond pulsed electric fields for melanoma malignancy treatment on tumorbearing BALB/c nude mice［J］. Technol Cancer Res Treat, 2014, 13(4): 337-344. DOI: 10.7785/tcrt.2012.500385. ［16］ Kirson ED, Gurvich Z, Schneiderman R, et al. Disruption of cancer cell replication by alternating electric fields［J］. Cancer Res, 2004, 64(9): 3288-3295. DOI: 10.1158/00085472. ［17］ Gutin PH, Wong ET. Noninvasive application of alternating electric fields in glioblastoma: a fourth cancer treatment modality［J］. Am Soc Clin Oncol Educ Book, 2012, 32: 126-131. DOI: 10.14694/EdBook_AM.2012.32.126. ［18］ Gera N, Yang A, Holtzman TS, et al. Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit［J］. PLoS One, 2015, 10(5): e0125269. DOI: 10.1371/journal.pone.0125269. ［19］ Kim EH, Song HS, Yoo SH, et al. Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis［J］. Oncotarget, 2016, 7(40): 65125-65136. DOI: 10.18632/oncotarget.11372. ［20］ Kirson ED, Dbal V, Tovarys F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors［J］. Proc Nat Acad Sci USA, 2007, 104(24): 10152-10157. DOI: 10.1073/pnas.0702916104. ［21］ Wenger C, Salvador R, Basser PJ, et al. The electric field distribution in the brain during TTFields therapy and its dependence on tissue dielectric properties and anatomy: a computational study［J］. Phys Med Biol, 2015, 60(18): 7339-7357. DOI: 10.1088/00319155/60/18/7339. ［22］ Stupp R, Wong ET, Kanner AA, et al. NovoTTF100A versus physician′s choice chemotherapy in recurrent glioblastoma: a randomised phase Ⅲ trial of a novel treatment modality［J］. Eur J Cancer, 2012, 48(14): 2192-2202. DOI: 10.1016/j.ejca.2012.04.011. ［23］ Stupp R, Taillibert S , Kanner AA, et al. Maintenance therapy with tumortreating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial［J］. JAMA, 2015, 314 (23): 2535-2543. DOI: 10.1001/jama.2015.16669. ［24］ Ansstas G, Tran DD. Treatment with tumortreating fields therapy and pulse dose bevacizumab in patients with bevacizumabrefractory recurrent glioblastoma: a case series［J］. Case Rep Neurol, 2016, 8(1): 1-9. DOI: 10.1159/000442196. ［25］ Wong ET, Lok E, Swanson KD. Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation［J］. Cancer Med, 2015, 4(3): 383-391. DOI: 10.1002/cam4.421. ［26］ Fonkem E, Wong ET. NovoTTF100A: a new treatment modality for recurrent glioblastoma［J］. Expert Rev Neurother, 2012, 12(8): 895-899. ［27］ Turner SG, Gergel T, Wu H, et al. The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTFTM100A system［J］. World J Surg Oncol, 2014, 12: 162. DOI: 10.1186/1477781912162.

[1]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞.原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[2]	肖楠, 孙鹏飞.氧化应激在胶质瘤放化疗敏感性中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(6): 357-361.
[3]	孔春禹, 孙鹏飞.SLC7A11与胶质瘤[J]. 国际肿瘤学杂志, 2022, 49(10): 604-607.
[4]	郭世豪, 任叶青, 郭庚.脑胶质瘤血管生成拟态分子机制[J]. 国际肿瘤学杂志, 2021, 48(6): 362-365.
[5]	王宪伟, 史美燕, 王凤芹, 齐福, 王朝喆, 周飞.TSA上调miR-4298靶向抑制PADI4表达在诱导U251细胞凋亡中的作用[J]. 国际肿瘤学杂志, 2021, 48(4): 193-199.
[6]	张雯, 胡伟国, 宋启斌.3D-ASL与DCE-MRI在脑胶质瘤复发与放射性脑坏死鉴别诊断中的价值[J]. 国际肿瘤学杂志, 2021, 48(10): 631-634.
[7]	赵聪选, 于韬.胶质瘤相关基因的挖掘及预测[J]. 国际肿瘤学杂志, 2020, 47(5): 293-296.
[8]	南阳, 钟跃.长非编码RNA在神经胶质瘤研究中的新进展[J]. 国际肿瘤学杂志, 2020, 47(2): 98-102.
[9]	张雯, 宋启斌, 胡伟国.多模态磁共振成像在脑胶质瘤中的临床应用[J]. 国际肿瘤学杂志, 2020, 47(11): 686-690.
[10]	陈亮, 秦军, 雷军荣, 刘俊, 王璐.miR-1254通过靶向CSF-1抑制胶质瘤细胞的增殖和侵袭能力[J]. 国际肿瘤学杂志, 2020, 47(10): 577-584.
[11]	张千慧, 张洋, 宿伟鹏, 张宋安, 刘攀, 赵化荣.LSD1、MGMT和Ki-67在高级别胶质瘤中的表达及对预后的影响[J]. 国际肿瘤学杂志, 2019, 46(9): 519-525.
[12]	衣琳, 邱实.紫草素抗胶质瘤效应及其作用机制[J]. 国际肿瘤学杂志, 2019, 46(8): 489-491.
[13]	于学娟, 安宏伟, 孙亚梅, 姜政, 张学海, 杨文敬, 张伟. MMP2、TIMP2、Ki-67、P53在胶质瘤组织中的表达及意义[J]. 国际肿瘤学杂志, 2019, 46(12): 718-722.
[14]	卢迪,张钧栋,郭庚,王小刚.干扰素通路中的关键分子诱导脑胶质瘤细胞凋亡的机制[J]. 国际肿瘤学杂志, 2018, 45(7): 432-435.
[15]	张园园，朱淑霞.微小RNA-495在神经胶质瘤中的作用机制[J]. 国际肿瘤学杂志, 2018, 45(6): 362-364.